Epicatechin is a promising novel inhibitor of SARS-CoV-2 entry by disrupting interactions between angiotensin-converting enzyme type 2 and the viral receptor binding domain: A computational/simulation study

Angiotensin-converting enzyme 2 (ACE2) is the first target of SARS-CoV-2 and a key functional host receptor through which this virus hooks into and infects human cells. The necessity to block this receptor is one of the essential means to prevent the outbreak of COVID-19. This study was conducted to...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Shuhaib, Mohammed Baqur S., Hashim, Hayder O., Al-Shuhaib, Jafar M.B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679518/
https://www.ncbi.nlm.nih.gov/pubmed/34942397
http://dx.doi.org/10.1016/j.compbiomed.2021.105155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679518/
https://www.ncbi.nlm.nih.gov/pubmed/34942397
http://dx.doi.org/10.1016/j.compbiomed.2021.105155

Ejemplares similares